Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Viridian Therapeutics, Inc.’s reported figures.
Plus components not separately reported this period.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
FAQ
- What is Viridian Therapeutics, Inc.'s EBIT?
- Viridian Therapeutics, Inc. (VRDN) reported EBIT of -$126.27M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s EBIT changed year-over-year?
- Viridian Therapeutics, Inc.'s EBIT decreased by 18.3% year-over-year, from -$106.77M to -$126.27M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s EBIT has grown at a 46.1% compound annual growth rate (CAGR), from -$79.73M to -$363.4M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Viridian Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude